非小细胞肺癌组织中RRM1的表达与含吉西他滨方案耐药的关系  

Relationship between RRM1 expression in non small-cell lung cancer tissue and gemcitabine-containing regimen resistance

作　　者：刘萍[1] 王豪勋[1] 

机构地区：[1]郑州大学第二附属医院肿瘤科,郑州450014

出　　处：《郑州大学学报（医学版）》2011年第6期876-878,共3页Journal of Zhengzhou University(Medical Sciences)

摘　　要：目的:探讨晚期非小细胞肺癌(NSCLC)组织中核糖核苷酸还原酶M1(RRM1)的表达与含吉西他滨方案耐药的关系。方法:将108例NSCLC患者均分为2组,试验组采用吉西他滨/顺铂(GP)方案治疗:吉西他滨1000mg/m2第1、8天静脉滴注,顺铂25mg/m2第1～3天静脉滴注,21d为1个周期;对照组采用紫杉醇/顺铂(TP)方案治疗:紫杉醇150mg/m2第1天静脉滴注,顺铂25mg/m2第1～3天静脉滴注,21d为1个周期。2个周期后评价疗效。应用免疫组化SP法检测2组患者NSCLC组织中RRM1的表达并分析其与含吉西他滨方案耐药的关系。结果:RRM1高表达与GP方案化疗耐药有关:GP方案化疗耐药组RRM1的高表达率为62.5%,明显高于敏感组(30.0%)(χ2=5.704,P=0.017)。RRM1高表达与TP方案化疗耐药无关(χ2=0.557,P=0.456)。结论:NSCLC组织中RRM1的表达升高与含吉西他滨方案耐药有关。Aim：To explore the relationship between the expression of RRM1 in non small-cell lung cancer（NSCLC） tissue and gemcitabine-containing regimen resistance.Methods：A total of 108 cases of NSCLC were allocated into 2 groups：54 cases were treated with gemcitabine and cisplatin（GP group）,54 cases were treated with paclitaxel and cisplatin （TP group）.All patients had received 2 cycles chemotherapy,and 21 days was a cycle.The expression of RRM1 in 108 cases of NSCLC tissue was detected by immunohistochemistry method and the relationship between the RRM1 expression and gemcitabin-containing regimen resistance was analyzed.Results：The high expression of RRM1 was associated with GP regimen resistance in NSCLC.The high expression rate of RRM1 in chemoresistant group was 62.5%,that of chemosensitive group was 30.0%,and the difference was significant（χ2=5.704,P=0.017）.The high expression of RRM1 was not associated with TP regimen resistance in NSCLC（χ2=0.557,P=0.456）.Conclusion：The high expression of RRM1 in NSCLC is related to gemcitabine-containing regimen resistance.

关 键 词：非小细胞肺癌 核糖核苷酸还原酶M1 吉西他滨 耐药 

分 类 号：R734.2[医药卫生—肿瘤]